Drugs / Entolimod
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03063736 | Dec 2017 → Mar 2018 | substance-related disorder | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT01728480 | Jan 2014 → Oct 2015 | hypopharynx squamous cell carcinoma, larynx verrucous carcinoma, mucositis, nasal cavity and paranasal sinus squamous cell carcinoma +4 | Roswell Park Cancer Institute | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT01527136 | Jan 2012 → Oct 2014 | cancer of unknown primary site | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04176133 | Oct 2019 → Mar 2022 | — | Robert J. Pignolo | Completed | No outcome recorded |
| Phase 2 | NCT02715882 | Nov 2015 → Feb 2017 | colorectal cancer | BioLab 612 LLC | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | entolimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01728480 ↗ |
| Known as | CBLB502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02715882 ↗ |
| Action | Activate | “Toll-like receptor 5 agonist” CHEMBL2108683 ↗ |
| Route | Intramuscular | “Patients receive entolimod intramuscularly (IM) on day 1 and subcutaneously (SC) on days 4, 8, and 11.” NCT01527136 ↗ |
| Route | Subcutaneous | “Patients receive entolimod intramuscularly (IM) on day 1 and subcutaneously (SC) on days 4, 8, and 11.” NCT01527136 ↗ |
| Target | TLR5 | “Toll-like receptor 5 agonist” CHEMBL2108683 ↗ |